Interaction of Serotonergic Antidepressants and Opioid Analgesics: Is Serotonin Syndrome Going Undetected?


      To describe the potential for interaction between opioids and serotonergic antidepressants leading to the development of serotonin syndrome (SS), mechanism of the interaction, and the spectrum of SS in elderly residents of a long-term care facility.


      Case series.


      Long-term care facility (LTCF) in California.


      Four elderly LTCF residents treated with serotonergic antidepressants including selective serotonin reuptake inhibitor (SSRI) or mirtazapine and opioids.


      Signs and symptoms suggestive of SS.


      We describe 4 cases of probable SS among elderly residents of a LTCF. The spectrum of serotonin toxicity ranged from visual hallucinations, muscle rigidity, myoclonus, or hypertension in patients taking an opiate with an SSRI to lethargy, hypotension, and hypoxia in a patient taking tramadol and mirtazapine.


      While many can benefit from coadministration of serotonergic antidepressants and opioids, it appears that some individuals are at increased risk for SS. Since SS is a clinical diagnosis, heightened clinician awareness of the possibility of SS among patients receiving SSRI or mirtazapine in combination with opioids may lead to earlier detection and avoidance of potentially lethal consequences.


      To read this article in full you will need to make a payment


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Teresi J.
        • Abrams R.
        • Holmes D.
        • et al.
        Prevalence of depression and depression recognition in nursing homes.
        Soc Psychiatry Psychiatr Epidemiol. 2001; 36: 613-620
      1. Diagnosis and treatment of depression in late life. NIH Consensus Development Conference reports. How prevalent is depression in the elderly and what are its risk factors? Available at: Accessed November 1, 2004.

        • Rovner B.W.
        • German P.S.
        • Brant L.J.
        • et al.
        Depression and mortality in nursing homes.
        JAMA. 1991; 265: 993-996
        • Lapane K.L.
        • Hughes C.M.
        An evaluation of the impact of the prospective payment system on antidepressant use in nursing home residents.
        Med Care. 2004; 42: 48-58
        • Simon G.E.
        • VonKorff M.
        • Piccinelli M.
        • et al.
        An international study of the relation between somatic symptoms and depression.
        N Engl J Med. 1999; 341: 1329-1335
        • Bair M.J.
        • Robinson R.L.
        • Katon W.
        • et al.
        Depression and pain comorbidity. A literature review.
        Arch Intern Med. 2003; 163: 2433-2445
        • Rosebraugh C.J.
        • Flockhart D.A.
        • Yasuda S.U.
        • et al.
        Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.
        J Clin Pharmacol. 2001; 41: 224-227
        • Ener R.A.
        • Meglathery S.B.
        • Van Decker W.A.
        • et al.
        Serotonin syndrome and other serotonergic disorders.
        Pain Med. 2003; 4: 63-74
        • Tao R.
        • Ma Z.
        • Auerbach S.B.
        Alteration in regulation of serotonin release in rat dorsal raphe nucleus after prolonged exposure to morphine.
        J Pharmacol Exp Ther. 1998; 286: 481-488
        • Tao R.
        • Auerbach S.B.
        GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system.
        J Pharmacol Exp Ther. 2002; 303: 704-710
        • Sternbach H.
        The serotonin syndrome.
        Am J Psychiatry. 1991; 148: 705-713
        • Radomski J.W.
        • Dursun S.M.
        • Reveley M.A.
        • et al.
        An exploratory approach to the serotonin syndrome.
        Medical Hypotheses. 2000; 55: 218-224
        • Stahl S.M.
        Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects.
        J Clin Psychiatry. 1998; 59: 23-29
        • Ubogu E.E.
        • Katirji B.
        Mirtazapine induced serotonin syndrome.
        Clin Neuropharmacol. 2003; 26: 54-57
        • Hagen N.
        • Swanson R.
        Strichnine like multifocal myoclonus and seizures in extremely high-dose opioid administration.
        J Pain Symptom Manage. 1997; 14: 51-58
        • Mittino D.
        • Mula M.
        • Monaco F.
        Serotonin syndrome associated with tramadol-sertraline coadministration.
        Clin Neuropharmacol. 2004; 27: 150-151
        • Houlihan D.J.
        Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.
        Ann Pharmacother. 2004; 38: 411-413
        • Biswas P.N.
        • Wilton L.V.
        • Shakir S.A.W.
        The pharmacovigilance of mirtazapine.
        J Psychopharmacol. 2003; 17: 121-126
        • Isbister G.K.
        • Whyte I.M.
        Adverse reactions to mirtazapine are unlikely to be serotonin toxicity.
        Clin Neuropharmacol. 2003; 26: 287-288
        • Gilman P.K.
        Clin Neuropharmacol. 2003; 26: 288-289
        • Faron-Gorecka A.
        • Kusmider M.
        • Inan S.Y.
        • et al.
        Effects of tramadol on α2-adrenergic receptors in the rat brain.
        Brain Res. 2004; 1016: 263-267
        • Mills K.C.
        Serotonin syndrome. A clinical update.
        Crit Care Clin. 1997; 13: 763-783
        • LoCurto M.J.
        Neurologic emergencies. The serotonin syndrome.
        Emerg Med Clin North Am. 1997; 15: 665-675
        • Skop B.P.
        • Finkelstein J.A.
        • Mareth T.R.
        • et al.
        The serotonin syndrome associated with paroxetine, an over- the-counter cold remedy, and vascular disease.
        Am J Emerg Med. 1994; 12: 642-644
        • Nisijima K.
        • Nibuya M.
        • Sugiyama H.
        Abnormal CSF monoamine metabolism in serotonin syndrome.
        J Clin Psychopharmacol. 2003; 23: 528-530